Since the year 2000, the reimbursement coverage and pricing rule for medical devices in South Korea has been evolving gradually with the introduction of the 'Value Appraisal Standard (VAS)' system in March 2006 to recognize the premium value of innovative medical devices. Nevertheless, the VAS system has been criticized due to the lack of objectivity and its insufficient operability. Over the last decade, the quest for a more comprehensive, structured and transparent reimbursement coverage decision-making process has prompted research into alternative decision-making frameworks. In this regard, multi-criteria decision analysis (MCDA) arose and has gained more attention as an approach to support healthcare decision-making involving multiple and conflicting criteria. In 2014 the task force initiated by both Ministry of Health and Welfare and Health Insurance Review and Assessment Service and composed of various stakeholder representatives was formed to improve the reimbursement coverage and pricing rule by leveraging international practices from foreign countries and to develop the most feasible pricing rule in the current healthcare policy environment. The task force studied the principles, processes and practices for reimbursement coverage and pricing of medical devices in other countries and also deliberated MCDA for improved and fair recognition of the value of innovative medical devices. The consensus for the improved reimbursement coverage and pricing rule with MCDA was reached among the stakeholders and placed into official regulation effective in January 2015. The MCDA application is expected to contribute to better innovation value recognition and also transparent and reasonable operation in the decision-making process.
Introduction
Since the year 2000, the reimbursement coverage and pricing rule for medical devices has been evolving gradually with the introduction of the 'Value Appraisal Standard (VAS)' system in March 2006 to recognize the premium value of innovative medical devices in South Korea. 1) Despite the evolutionary improvement, the VAS system has been criticized about its lack of objectivity and transparency and also insufficient recognition of innovative medical device values. In theory, innovative medical devices are potentially eligible for a 10 to 50% premium price over the existing listed medical devices through the VAS application. In practice, however, the cases of VAS application for innovative medical devices are few and the extent to which premium prices are granted remain at best at only 10% in most cases. Given this situation, it is warranted to argue that this environment may act not only as a barrier to patient access of innovative medical devices but may also impede medical device industry research and development. According to the statistical data provided by the Ministry of Health and Welfare (MoHW) and Health Insurance Review and Assessment Service (HIRA), 252 products (4.75%) out of 5301 reimbursement application medical devices were granted for premium prices over a four year period (from 2010-2013)-10% premium for 244 products (4.6%), 20% premium for 6 products, 30% premium for 1 product, 50% premium for 1 product and collectively 8 products (0.15%) with more than 20% premium prices were granted.
2) Contrary to the authorities' interpretation of the statistical data, the medical device industry has a different perspective. Further investigation found that most of the products that went through the VAS were in fact not given a 'premium price' but rather
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were assigned the highest ceiling reimbursement price of existing listed medical devices. In reality, only 36 products were granted premium prices from a total number of 5301 products, making the true estimate of premium prices granted only 0.7%. Also, the manufacturer that was granted a 50% premium price for its product withdrew its application due to an unmarketably low price decision. One of the major reasons few cases of premium-priced products have been approved in the past may originate from the challenge medical device manufacturers have in generating robust clinical evidence (e.g., randomized controlled trials, large sample size studies, long-term data, etc.) and sound cost-effectiveness analyses compared to pharmaceuticals. [3] [4] [5] Medical devices are uniquely different to drugs in that they undergo continual iterations and improvements (such as miniaturizations, longer battery life, etc.) which can improve patient benefits (such as reduce pain) over time; there is often a 'learning curve' associated with a device (especially those devices used in surgery) that can adversely affect new and innovative devices; some devices are also diagnostic making their value inherently linked to subsequent improvement in patient outcomes. All of these factors make generation of clinical and economic evidence more challenging. 4, 5) Other factors to consider would be medical devices such as theatre consumables, non-implantables and orthopedic implants, which often have little robust clinical evidence of efficacy making those devices a challenge to obtain premium prices through the VAS. Domestic medical device manufacturers which are mostly small-sized/mid-sized companies have little resources and capability to generate clinical evidence, which has raised the fairness issue in VAS operation. In addition, domestic manufacturers argue that it is not fair to request robust clinical evidences within short period of time after regulatory approval. The reimbursement regulation demands applicants submit reimbursement applications within 30 days post regulatory approval and clinical evidences to meet reimbursement criteria. These are evidences not usually requested at the time of regulatory approval. Meanwhile foreign manufacturers had already generated clinical evidences in foreign markets prior to market entry into South Korea, domestic manufacturers never had an equal chance to produce evidences before reimbursement approvals. Indeed, domestic manufacturers obtained a 10% premium for only 13 products through the VAS over the same period (2010-2013).
Bringing Multi-Criteria Decision Analysis into the Discussion
In May 2014, the MoHW and HIRA formed a task force composed of various stakeholder representatives from health authorities, medical device manufacturers, healthcare providers, civic groups, academia, etc. to respond to the criticisms of the VAS. The main initiatives of the task force were described as follows: 1) establishment of objective criteria for value appraisal candidate products, 2) improvement of the VAS and premium rating system, 3) discussion of a premium granting method, and 4) establishment of a Value Appraisal Expert Committee composition and its operation method. "Evidence and Value: Impact on DEcision Making framework" which is one of methods of MCDA was brought to the discussion in order to enhance reasonableness through an academically proven value appraisal index, to improve objectivity through a concrete appraisal method, and to diversify the appraisal categories more than the current clinical usefulness (e.g., therapeutic effects and quality of life) and cost-effectiveness aspects. 6) Traditionally, health authorities or relevant organizations such as National Institute for Health and Care Excellence have adopted cost-effectiveness analysis to rule on market access, using the quality-adjusted life-year (QALY) to measure benefits. However, there are several limitations of this approach. For example, the QALY does not capture the full impact of an intervention including disease severity, target population size, economic impact, evidence quality and/or political factors. Due to those deficiencies, MCDA has been introduced due to its potential to consider complex and diverse criteria and if done well, it can support transparent and consistent decision-making. [7] [8] [9] [10] MCDA is an extension of decision theory that supports decision-makers (policy makers, regulators, etc.) who have multiple (possibly conflicting) objectives by deconstructing the decision objectives into defined logical criteria. 11) These criteria are given a numeric importance weight and decision alternatives such as drugs or treatments are scored on each of the criteria. The criteria weights and performance scores are then aggregated into overall scores, which are used to rank the alternative treatments. It is a more formal, structured, comprehensive and transparent framework than costeffectiveness analysis and a solely more deliberative process. In addition, there are different approaches to MCDA, some of these include; value measurement, outranking and goal programming. The appropriate approach depends on the specific problem and user demands. 12, 13) MCDA has been applied in many settings, including transport, environmental protection, construction, and finance, 14) however, its application has been limited in healthcare. In a recent review of MCDA use in the assessment of value in healthcare it was found that of the 41 examples identified, more than half of the identified studies using MCDA were published since 2011.
15) The review found that MCDA use in healthcare was designed mainly to inform coverage and reimbursement decisions which accounted for 56% of all included studies, followed by prescription decisions (22%), authorization (12%), and research fund-ing allocation decisions (2%) were among the examples of MCDA applications. Closer examination into the use of MCDA in healthcare revealed the US Institute of Medicine has recently proposed an MCDA-based prioritization framework for vaccines. 16) In addition, the Institute for Quality and Efficiency in Health Care in Germany has explored a form of MCDA-Conjoint Analysis and Analytical Hierarchy Process (AHP)-to weight the multiple endpoints considered in its assessments.
17) The Advisory Group for National Specialized Services in the UK developed a MCDA-based decision-making framework to support reimbursement decisions for orphan drugs. 18) To date, there are very few applications of MCDA for the medical device sector.
VAS Revision with MCDA Application
The various appraisal categories in the VAS were discussed, considering difficulties of appraisal item selection due to a variety of medical device characteristics and diversified clinical usefulness, etc. and a decision was made to select suitable appraisal categories for each product application and grant weights and scores accurately. In addition, an AHP was used to provide objective appraisal categories and weights 19) and finally the amended regulation and its operating regulation were enacted. 20, 21) The newly developed 'operating regulation for VAS of medical devices' specifies the method, process and other necessary details in operating the VAS. The main changes are as follows.
First, improvement in the objectivity of selection criteria for value appraisal and maximum premium price with VAS: the revised VAS has combined two separate VAS (VAS I and II) and divided the clinical usefulness category into two tracks (clinical usefulness ' A' and 'B') to encompass any non-clinical evidence. The clinical usefulness 'B' category was created to reflect the difficulty in generating clinical evidence for various medical devices particularly developed from domestic manufacturers. To avoid subjective judgment issues, objectivity is enhanced by subdividing the value appraisal categories and allocating weights to each appraisal category. When an applicant proves the clinical usefulness through clinical evidence, they are eligible for a maximum 100% premium price to be granted. Also a maximum 50% premium price can be granted when the technological and functional evidence based on the Technical File which is submitted to the Ministry of Food and Drug Safety (MFDS, formerly known as Korea Food and Drug Administration) for regulatory approval purpose, etc. are provided without clinical evidence (Table 1) . For the value appraisal, the submission of clinical usefulness documents (e.g., clinical evidence or technological and functional evidence, etc.) is mandatory. Evidence requirements are specified and an objective appraisal principle of Evidence-Based Medicine is established. For the objective and reasonable decision-making criteria, the level and quality of evidence are considered and a weight and score for each appraisal category are established. The total scores are calculated by multiplying the weight and score for each appraisal category and summing up the scores (Table 2, 3). HIRA went through expert consultation meetings consisting in total of 35 experts and a largescaled expert consultation process with a total of 300 members from the Medical Device Expert Evaluation Committee to establish each appraisal category and weight by using the AHP. 22) Second, the establishment of operating criteria by the Value Appraisal Committee and enhancement of the appraisal process resulting in improved transparency: the criteria of the Value Appraisal Committee have been established to improve transparency and consistency in value appraisal operation. By establishing the requirement of committee composition and operation, transparent and objective appraisals are expected to be made for candidate products of the value appraisal, value appraisal scoring system, and appraisal opinion sections. Contrary to the former decision-making process, there is now an opportunity to present information on the innovativeness of the medical device application by 1 or 2 clinical experts that have been recommended by the applicant. The final result of the value appraisal is made available to the applicant via written or electronic correspondence and the result is also made available to the public (except any commercial-in-confidence data), to improve the consistency and transparency in the decision-making process. 23, 24) As part of the new process, the Value Appraisal Committee are provided with (Table  4) . 25) The clinical literature quality assessment is an evaluation tool of risk of bias for randomized studies and utilizes the 'Cochrane Collaboration' s Risk of Bias' tool (Table 5 ). For the evaluation of risk of bias for non-randomized studies, the 'Risk of Bias for Nonrandomised Studies' tool is used (Table 6) . [26] [27] [28] Third, appraisal category development to promote evidence generation and technology innovation: regardless of the final result of the quality assessment of the clinical literature, there is a provision in the new process that ensures that applications for innovative medical devices receive a minimum score. For example, when clinical evidence of a category 3 hierarchy is submitted, a minimum score of 1 is granted. When clinical literature of a category 1, 2, or 3 is submitted but with evidence in a Korean population, a minimum score of 2 is granted. In terms of the appraisal categories for cost effectiveness, when more than two factors are met, a minimum score of 1 is granted. For the technology innovation appraisal category, when more than one factor is met, minimum scores of 2 or 3 are granted. The technology innovation appraisal category is a newly created category that includes the New Excellent Technology certification, award record relevant to healthcare technology, and the National research and development (R&D) program evaluation result, etc. to encourage local research activities and local medical device development. 29) Also, in order to promote local manufacturer' s effort for superior medical device development, an extra 5% premium price is granted when clinical research is conducted in MoHW-accredited clinical research centers or research-oriented hospitals and finally the clinical evidence is submitted. 30) Lastly, re-evaluation of value appraised medical devices: the re-evaluation of value appraised medical devices is made through reimbursement claim trend analysis to effectively manage them after a few years of the value appraisal announcement.
Discussion
The revised VAS was established to significantly improve the problems of objectivity, fairness, and transparency from the former VAS which has been in operation over the past 8 years. South Korea's reimbursement coverage and pricing system requires reimbursement applications for all medical This can be practically very challenging for manufacturers to have robust clinical evidence for all medical devices they produce. Considering South Korea's medical device management environment which has different characteristics compared to that of pharmaceutical products, it is encouraging to have the application of MCDA improve the VAS system, providing consistent and transparent appraisal criteria and categories. Leaving economic evidence aside, it was essential to improve the decision-making process for medical devices that receive insufficient reimbursement due solely to the lack of clinical evidence. Indeed for many types of medical devices, especially consumables, non-implantables or single-use products demonstrating value with non-clinical data (mechanical or functional test data) is more appropriate than performing large clinical trials. In this regard, the divided clinical usefulness appraisal category (e.g., clinical usefulness ' A' and 'B') aims to solve such practical problems. In spite of positive feedback on the revised VAS with application of MCDA, there are some factors to consider in the future. Firstly, in regards to improving the objectivity in appraisals: although the objectivity in the appraisal process has been improved with the introduction of MCDA, subjectivity in the appraisal process through the VAS and the development of the value appraisal operating regulation means that the issue of being completely objective is not entirely resolved. This issue of subjectivity is inevitable due to the characteristics of medical devices (e.g., the large variety of medical devices and their different value determining factors) along with a potential deficiency of robust clinical evidence (e.g., in terms of evidence quality and quantity). To assist in the issue of subjectivity during the appraisal process, the selection of experts in the Value Appraisal Committee that are capable of accurately and objectively appraising evidence would be a desirable addition in the process.
Secondly, the necessity of including a differentiated weight allocation in each medical device functional group by considering its characteristics: considering the variety of medical devices, it is a more reasonable approach to allocate a differentiated weight in each medical device functional group for each appraisal category. To date, the Korea Medical Devices Industry Association has conducted a simulation process for applying differentiated weights in each major functional group in the appraisal categories-namely; an overall functional group, the orthopedic group, the cardiovascular group, the human tissue group, and a general consumable group. 31) Although this simulation has its limitations, it was found that a difference in weighting can be identified by functional group. For instance, the orthopedic group had relatively higher weights in the appraisal category at 'patient quality of life improvement' , 'functional improvement' , and 'procedural easiness' than other appraisal categories. In comparison, the category 'adverse effect improvement' had a relatively lower weighting. The cardiovascular group had higher weight placed on the category 'therapeutic effects improvement' than the other appraisal categories and the general consumable group had higher weight on the 'functional improvement' and 'procedural easiness' categories compared to the others (Table 6) . 31) Consequently, this simulation analysis demonstrates that it may be necessary to develop differentiated weights by functional category groups in order to provide the most appropriate values for each product group.
Thirdly, the creation of a new functional category group for value-appraised products: it is very important to accurately create new functional category groups for the value-appraised products in value recognition. As the cost, effectiveness or functionality are the current criteria used to judge the same functional category, it may be more appropriate to create new functional categories for the value-appraised products which prove the improvement of clinical usefulness, cost effectiveness and technology innovation. If the value-appraised product is placed in an existing functional category, the risk of unexpected price erosion will increase which as discussed previously will adversely affect the value of innovation of that product. Indeed, the creation of a new functional category was hotly disputed during the task force discussions but a final agreement between the authorities and industry on this matter was not made. Fourth, the promotion of economic value evidence development: while pharmacoeconomic evidence is currently a requirement for the reimbursement of new drugs, 32) the economic evaluation requirement for medical devices is still under discussion. The medical device industry has requested the authority to grant more than 100% premium price when an applicant submits sound economic evaluation evidence. Hence, the requirement for an evaluation of economic evidence is currently pending. Contrary to drugs, medical devices have a number of challenges when it comes to conducting economic evaluations. For domestic medical device manufacturers, their inability to properly invest in product R&D and clinical trials limit their ability to generate economic evidence for use in an evaluation. For many global medical device companies currently operating in South Korea, a lack of local health economists that have the skillsets to develop and run complex economic models has meant support is always required from global headquarters. Unfortunately this support is often not available. In many countries, submission of a formal economic evaluation for the purposes of medical device reimbursement is not a mandatory requirement for coverage (for example, prosthesis list submissions for funding of medical devices in the private sector in Australia, or 'NUB' submissions for short-term funding of innovative medical devices in Germany). Very few new and innovative medical devices have economic evidence that can be used in an evaluation. This is a global and industry wide issue. Over time, however, medical devices that are well established in the treatment pathway of a particular disease or have become standard of care, such as drug eluting stents and pacemakers for example, typically have robust clinical (efficacy and safety) and economic evidence available. Yet, it is very difficult to expect new and innovative medical devices have the same high level of clinical and economic evidence similar to what is available for drug-eluting stents for example. 33) Nevertheless, the incentivized system for encouraging economic evidence generation is required to supplement the integrity of reimbursement coverage and pricing decision-making.
Conclusion
Revising the VAS system with the application of MCDA is expected to address the lack of objectivity, fairness and transparency which have been criticized as characterizing the current process of innovative medical device reimbursement and pricing. It is meaningful that various key industry, government and other stakeholders convened to discuss and assist in setting out clear improvements in the decision-making process for reimbursement coverage and pricing practice. Importantly however, it shall be indicated that MCDA should not be applied in a formulaic manner, but as the basis for deliberation to ensure that context-specific factors are incorporated into an assessment. In the future, careful monitoring of the revised VAS system is warranted, so that additional improvements and adjustments can be made to enhance the reimbursement decision-making process.
